FDA approval decisions this week: Oct 5 to Oct 11, 2026
Page updated ·next FDA decision on the calendar·Data as of Oct 11, 2026 9:31 PM ET
In the week of Oct 5 to Oct 11, 2026, the FDA decided 2 tracked applications: RHHBY Tecentriq (atezolizumab) (Approved, October 8, 2026); NVS Rhapsido (remibrutinib) (Approved, October 6, 2026). 0 goal dates remain this week. As of October 11, 2026 (Eastern). Dates come from FDA records and company filings; no approval odds, no predictions.
Every FDA decision date on pdufa.bio comes from the FDA's own record where one is held, otherwise from the sponsor's announcement, and the page says which. See today, this month, the full PDUFA calendar and every FDA approval letter. Informational only; not investment advice.
Questions
Which drugs did the FDA approve this week?
In the week of Oct 5 to Oct 11, 2026 the FDA decided 2 tracked applications: RHHBY Tecentriq (atezolizumab) (Approved, October 8, 2026); NVS Rhapsido (remibrutinib) (Approved, October 6, 2026), as of October 11, 2026.
Which FDA decisions are still due this week?
No further goal dates fall in this week. A goal date is the FDA's target, not a promise of a decision that day.
Where do these dates come from?
From the FDA's approval letters, Drugs@FDA and FDA notices for decisions, and from SEC filings and company releases for goal dates. Each row links its page and source.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.